Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

l minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. A replay of the webcast will be archived on the Sunesis website for two weeks until March 25, 2008.

About Sunesis' Oncology Programs

Sunesis has built a portfolio of product candidates in oncology focused on inhibition of the cell-cycle and survival signaling. Our lead product candidate, SNS-595, is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. SNS-595 is a specific DNA intercalator and topoisomerase II poison, causing replication-dependent site-selective double-strand DNA damage, irreversible G2 arrest and rapid apoptosis. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b clinical trial of SNS-595 combination with cytarabine in relapsed/refractory AML are both ongoing. SNS-032, a potent and selective inhibitor of CDKs 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory CLL or multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other protein kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information o
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... DALLAS and NEW YORK ... Inc. (NASDAQ: PTBI ), a biopharmaceutical company ... products, announced today that its Korean marketing partner, ... received marketing approval in Korea from the country,s ... the Korea Testing & Research Institute (KTR) for ...
(Date:3/31/2015)... CA (PRWEB) March 31, 2015 This ... Professors from the top U.S and International Medical Schools ... their latest research on the application of stem cell ... The symposium is organized and funded by the ... nonprofit that has been convening intimate meetings of top ...
(Date:3/31/2015)... Diasome Pharmaceuticals, Inc. ( http://www.diasome.com ) has received ... States patent has recently been allowed for the Company’s ... “Lipid Construct for Delivery of Insulin to a Mammal,” ... the use of Diasome’s proprietary Hepatocyte Directed Vesicles (“HDV”) ... effectively reach the liver’s metabolic cells, called hepatocytes. , ...
(Date:3/30/2015)... 2015 With recent advancements in residential ... government, major companies are getting into the Solar Energy ... mandates for renewable energy production, many homeowners are looking ... Power is a new solar distribution company in California ... allow qualifying homeowners to enjoy the benefits of solar ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3Sight Restoration Through Stem Cell Therapy - Subject of June Symposium of Experts 2Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2Solara Power Announces Residential Solar Power with No Up-Front Fees 2
... July 11, 2011 MRIGlobal, an internationally recognized ... the U.S. and overseas, has appointed Richard A. Winegar, ... http://photos.prnewswire.com/prnh/20110711/DC32923 ) Dr. Winegar is ... in radiation biology and genetic toxicology.  As Principal Advisor ...
... WORCESTER, Mass. and TORONTO, July 11, 2011 ... announced today the publication of studies conducted at ... Ii-Key technology.  Antigen Express, Inc., the Company,s wholly-owned ... development of self-potentiating immunotherapeutic vaccines for cancer.  AE37, ...
... York, NY July 10, 2011 Researchers at ... them to engineer the index of refraction and fully ... possible for light (electromagnetic waves) to propagate from point ... through the artificial medium as if the medium is ...
Cached Biology Technology:MRIGlobal Appoints Richard A. Winegar, Ph.D., as Principal Advisor for Science 2Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 2Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 3Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 4Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology 5Light propagation controlled in photonic chips -- major breakthrough in telecommunications field 2
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
(Date:3/20/2015)... DUBLIN , Mar. 20, 2015 Research ... announced the addition of the "India Sensors ... their offering. The sensor market is ... through 2020 Consumer electronics, automotive, industrial ... for sensors in the country. In addition, adoption ...
(Date:3/19/2015)... OXFORD, Conn. , March 19, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce market, ... featured in a news clip that aired this week on ... http://www.myfoxdc.com/ ) . In a segment "The Next ... smart wallet ,a new way to pay, and ,a really ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... the Colorado High School Science Bowl today. They will go ... Apr. 25-29, where they will compete for the national title ... The U.S. Department of Energy (DOE) began the Science Bowl ... students to explore math and science. The Department of Energy,s ...
... journal Nature Chemical Biology , scientists Carole ... University), and Andrew D. Hanson (University of Florida, ... part of metabolism, namely metabolite damage-control. In their ... the authors present a comprehensive overview of the ...
... ingredient lists and consumer product guides appearing on cleaning ... topic of the cover story in Chemical & ... the American Chemical Society, the world,s largest scientific society. ... McCoy explains that cleaning products are at the forefront ...
Cached Biology News:How our cells cope with toxic small molecules 2
... For the ultimate in utility and flexibility ... meet the needs of the researcher. They ... dimensions or as sheet material that can ... These isolators are autoclavable and non-cytotoxic and ...
... mycobacteria found in Complete Freund's Adjuvant so it ... Freund's Adjuvant is used for the ... produce water-in-oil emulsions of immunogens. Antigens ... responses which can be attributed to the slow ...
2,4-Dinitrophenyl hapten is conjugated to Keyhole Limpet (KLH) protein through lysine....
PGF1α-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGF1α by GC- or LC-mass spectrometry....
Biology Products: